KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30

KAZIA THERAPEUTICS LTD

Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 7, 2025

$7.85+0.60 (+8.28%)

Close on Oct 19, 2026

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Kazia Therapeutics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Kazia Therapeutics filed with the SEC

Sep 22, 2026, 8:00 AM ET
PRESS RELEASE DATED SEPTEMBER 22, 2026
EX-99.1 to Form 6-K
Sep 1, 2026, 4:55 PM ET
PRESS RELEASE DATED SEPTEMBER 1, 2026
EX-99.1 to Form 6-K
Sep 1, 2026, 4:55 PM ET
PRESS RELEASE DATED SEPTEMBER 1, 2026
EX-99.2 to Form 6-K
Aug 31, 2026, 6:14 AM ET
LAUNCH PRESS RELEASE OF KAZIA THERAPEUTICS LIMITED DATED AUGUST 27, 2026
EX-99.1 to Form 6-K
Aug 31, 2026, 6:14 AM ET
PRICING PRESS RELEASE OF KAZIA THERAPEUTICS LIMITED DATED AUGUST 28, 2026
EX-99.2 to Form 6-K
Aug 27, 2026, 4:37 PM ET
PRESS RELEASE DATED AUGUST 27, 2026
EX-99.1 to Form 6-K
Aug 27, 2026, 4:37 PM ET
INVESTOR PRESENTATION DATED AUGUST 27, 2026
EX-99.2 to Form 6-K
Jul 28, 2026, 7:30 AM ET
PRESS RELEASE DATED JULY 28, 2026
EX-99.1 to Form 6-K
Jun 2, 2026, 9:00 AM ET
PRESS RELEASE DATED JUNE 2, 2026
EX-99.1 to Form 6-K
May 26, 2026, 8:00 AM ET
PRESS RELEASE DATED MAY 26, 2026
EX-99.1 to Form 6-K
Apr 27, 2026, 8:30 AM ET
INVESTOR PRESENTATION DATED APRIL 27, 2026
EX-99.1 to Form 6-K
Apr 27, 2026, 8:30 AM ET
FACT SHEET DATED APRIL 27, 2026
EX-99.2 to Form 6-K
Apr 15, 2026, 8:30 AM ET
PRESS RELEASE DATED APRIL 15, 2026
EX-99.1 to Form 6-K
Apr 13, 2026, 5:24 PM ET
PRESS RELEASE DATED APRIL 13, 2026
EX-99.1 to Form 6-K
Mar 31, 2026, 4:56 PM ET
INVESTOR PRESENTATION DATED MARCH 27, 2026
EX-99.1 to Form 6-K
Mar 31, 2026, 4:56 PM ET
FACT SHEET DATED MARCH 27, 2026
EX-99.2 to Form 6-K
Mar 30, 2026, 6:08 AM ET
Yearly Report - 31 December 2025
EX-99.1 to Form 6-K
Mar 19, 2026, 5:09 PM ET
Half Yearly Report - 31 December 2025
EX-99.1 to Form 6-K
Jan 27, 2026, 8:10 AM ET
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative
EX-99.1 to Form 6-K
Dec 10, 2025, 4:11 PM ET
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib’s Ability to Reinvigorate Anti-Tumor Immunity
EX-99.1 to Form 6-K
Dec 2, 2025, 4:05 PM ET
Kazia Therapeutics Announces Pricing of
EX-99.1 to Form 6-K
Oct 7, 2025, 5:17 PM ET
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
EX-99.1 to Form 6-K
Oct 2, 2025, 8:55 AM ET
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
EX-99.1 to Form 6-K
Sep 11, 2025, 9:11 AM ET
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib
EX-99.1 to Form 6-K
Aug 1, 2025, 8:14 AM ET
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market
EX-99.1 to Form 6-K
Jul 9, 2025, 4:05 PM ET
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen
EX-99.1 to Form 6-K
Jun 11, 2025, 4:29 PM ET
Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisibs Potential to Overcome Immunotherapy Resistance in
EX-99.1 to Form 6-K
Jun 10, 2025, 4:05 PM ET
Half Yearly Report - 31 December 2024
EX-99.1 to Form 6-K
Jun 5, 2025, 9:20 AM ET
Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
EX-99.1 to Form 6-K
May 15, 2025, 8:15 AM ET
Progress and Provides Business Update
EX-99.1 to Form 6-K
Mar 31, 2025, 8:39 AM ET
Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
EX-99.1 to Form 6-K
Mar 13, 2025, 7:00 AM ET
Contents 2 4 6 Chairman and Key About GBM CEOs Letter Milestones 8 12 Environment, Financial Society & Reports Governance
EX-99.1 to Form 6-K
Feb 20, 2025, 4:51 PM ET
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of
EX-99.1 to Form 6-K
Feb 3, 2025, 8:36 AM ET
Corporate Overview January 2025 NASDAQ: KZIA | X: @KaziaTx
EX-99.1 to Form 6-K
Jan 30, 2025, 7:57 AM ET
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in
EX-99.1 to Form 6-K
Jan 13, 2025, 8:03 AM ET
Kazia Therapeutics Announces $2.0 Million Registered Direct Offering
EX-99.1 to Form 6-K
Dec 31, 2024, 8:43 AM ET
on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
EX-99.1 to Form 6-K
Dec 11, 2024, 8:58 AM ET
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative
EX-99.1 to Form 6-K
Nov 4, 2024, 4:33 PM ET
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed
EX-99.1 to Form 6-K
Nov 4, 2024, 4:33 PM ET
Corporate Overview November 2024 NASDAQ: KZIA | X: @KaziaTx
EX-99.2 to Form 6-K

Where these numbers come from

Parsed from the XBRL in Kazia Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Apr 17, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KZIA.

Revenue growth-98.2% · median -72.8%

Net margin-49290.5% · median -467453.1%

Company	Revenue	Growth
LSTA	$100.00K	-90.7%
KZIA	A$42.00K	-98.2%
LYEL	$27.00K	-55.0%
CNBX	$0	–
NTHI	–	–
KPRX	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 14
Held by institutions: 0.4%
Auditor: BDO Audit Pty Ltd
SEC CIK: 1075880

Advertisement
300 × 250